Previous animal studies have demonstrated increased efficacy of combining RAD001 with Neoral, potentially allowing lower Neoral doses and fewer side effects. Safety and tolerability of RAD001 have been demonstrated in stable renal transplant patients. This study involves two 3-day inpatient stays approximately a week apart during which multiple blood samples are drawn following the oral administration of 2 different doses of the study medication, RAD001. Bloodwork, ECG, and spirometry are also done on an outpatient basis for approximately 8 days. The total study time is 22 days.
Some reimbursement is available and all testing is covered by the company.
This is a one year study that involves weekly and then monthly visits to Stanford for bloodwork, ECG, physical exams, spirometry, and quality of life questionnaire completion. All testing is covered by the company. This is a three year out-patient study that involves weekly, monthly and then quarterly visits to Stanford for bloodwork, ECG, physical exams, spirometry and quality of life questionnaire completion. All testing is covered by the company. This 12 week study is investigating the effectiveness of the continuous subcutaneous infusion of UT 15, a prostacyclin analogue with potent vasodilatory and platelet anti-aggregatory actions, in patients with primary or secondary pulmonary hypertension.